NEW YORK, May 8 – Saiid Zarrabian, who resigned as chief operating officer at Pharmacopeia in December, has been appointed president and COO of Senomyx, a developer of flavor and fragrance molecules that can be used in consumer products, Senomyx said Tuesday.

"Mr. Zarrabian brings tremendous knowledge to Senomyx, particularly in the area of chemical and biological simulations and analysis systems, as well as drug discovery process,” Senomyx CEO Paul Grayson said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.